Financial Performance - The company's operating revenue for 2023 was CNY 2,105,249,607.06, representing a 33.87% increase compared to CNY 1,572,568,513.46 in 2022[21]. - The net profit attributable to shareholders for 2023 was CNY 130,870,579.41, a decrease of 295.57% from CNY 66,916,009.08 in 2022[21]. - The net cash flow from operating activities decreased by 60.91% to CNY 41,708,735.81 in 2023 from CNY 106,707,621.94 in 2022[21]. - The total assets at the end of 2023 were CNY 7,056,973,990.00, an increase of 3.53% from CNY 6,816,635,272.00 at the end of 2022[21]. - The basic earnings per share for 2023 was -CNY 0.34, compared to CNY 0.22 in 2022, reflecting a 300.00% decrease[21]. - The total revenue for 2023 reached ¥2,105,249,607.06, representing a year-on-year increase of 33.87% compared to ¥1,572,568,513.46 in 2022[84]. - The health protection products segment generated ¥1,833,718,412.78, accounting for 87.10% of total revenue, with a growth of 19.06% from ¥1,540,100,417.09 in the previous year[85]. - The safety infusion products segment saw a remarkable increase of 804.14%, with revenue of ¥213,262,874.62 compared to ¥23,587,266.27 in 2022[85]. - The innovative incubation products segment reported revenue of ¥58,268,319.66, marking a significant growth of 556.11% from ¥8,880,830.10 in the previous year[85]. - The gross profit margin for the medical device industry was 12.10%, with a year-on-year increase of 2.40%[86]. Market Trends and Opportunities - The global medical device market is expected to grow significantly due to increasing health awareness and government policies supporting medical technology[34]. - The global demand for nitrile gloves has shown signs of recovery, with manufacturers experiencing a significant increase in quality orders[38]. - The market for natural latex gloves is expected to improve as inventory depletion nears completion and demand increases[39]. - The government has emphasized the importance of enhancing medical service systems, which will provide further opportunities for the medical device industry[34]. - The global market for safety infusion products is expected to grow steadily, with China's safety infusion consumables holding the largest market share in low-value medical consumables[41]. - The global condom market size increased from $4.36 billion in 2015 to $7.03 billion in 2020, with a compound annual growth rate (CAGR) of approximately 10%[42]. - The domestic condom sales grew from 1.04 billion RMB in 2015 to 12.2 billion RMB in 2019, reflecting a CAGR of about 20%[43]. - The global market for infusion pumps is projected to reach approximately $18.92 billion by 2027, with an estimated market volume of 5.6 million units in 2022[44]. Product Development and Innovation - The company is continuously improving its R&D capabilities and enriching its product line to enhance competitiveness[4]. - The company is focusing on life support, minimally invasive consumables, and rehabilitation equipment for future product development and acquisitions[57]. - The company has developed over 100 different types of condoms and has received medical device registration for polyisoprene male condoms, enhancing its product range[51]. - The company is developing a new type of nitrile glove with a silicone oil content of less than 0.4ng/cm2 to enhance product competitiveness and attract new customers[95]. - The company is working on a high-durability nitrile glove to meet the needs of the food processing and aquaculture industries, aiming to improve product quality and profitability[95]. - The company has developed high-performance nuclear radiation protective gloves, enhancing its core competitiveness in both domestic and international markets[97]. - The company has introduced a water-based dialysis paper for syringes, which is expected to lower production costs and enhance product competitiveness[97]. - The company has implemented advanced manufacturing techniques for its medical devices, ensuring high-quality standards and safety, such as using medical-grade materials for its disposable injection devices[64]. Acquisitions and Strategic Investments - The company acquired a 70% stake in Maiderna, which specializes in infusion pumps and related systems, to strengthen its product offerings in the infusion market[56]. - The company completed the acquisition of 70% of Guilin Hengbao Health Protection Co., enhancing its product offerings in medical gloves and condoms[91]. - The acquisition of 70% of Shenzhen Maide Ruina Biotechnology Co. was finalized, expanding the company's capabilities in infusion pumps and related technologies[91]. - The company is currently undergoing significant non-equity investments, although specific details were not disclosed in the report[116]. - The company is actively seeking high-quality investment targets for mergers and acquisitions to expand its operational scale and optimize product structure[153]. Governance and Compliance - The company has a robust internal control system and governance structure, ensuring compliance with the "Corporate Governance Code" and other relevant regulations[166]. - The independent directors actively participated in the company's operations and provided professional advice on strategic development and internal control[168]. - The company has established three specialized committees under the board of directors to provide scientific and professional decision-making advice[168]. - The company has maintained a transparent relationship with investors, ensuring equal access to information and protecting the rights of minority shareholders[170]. - The governance structure is compliant with relevant laws and regulations, ensuring effective operation of the board and management[164]. Future Outlook and Strategic Goals - The company plans to focus on the medical health sector in 2024, aiming to become a leading comprehensive supplier of medical health products and services globally[146]. - The company aims to maintain its leading position in the surgical glove market, targeting to be the number one in China and top three globally[146]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[188]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25% based on new product launches and market expansion strategies[188]. - The company aims to improve its market capitalization through strategic initiatives[151].

Zhonghong Medical 2023 Corporate Social Responsibility Report About This Report About This Report This is the second Corporate Social Responsibility Report disclosed by Zhonghong Pulin Medical Products Co., Ltd. Based on the principles of standardization, transparency, objectivity, and comprehensiveness, the report presents stakeholders with the social responsibility practices and performance of Zhonghong Medical in the aspects of operation, environment, society, and charity. Basis of Preparation This repor ...

公司按照风险导向原则确定纳入评价范围的主要单位、业务和事项以及高风 险领域。纳入评价范围的主要单位包括:中红普林医疗用品股份有限公司及合并 报表范围内所有子公司,纳入评价范围单位资产总额占公司合并财务报表资产总 额的 100%，营业收入合计占公司合并财务报表营业收入总额的 100%。 纳入评价范围的业务和事项包括内部环境、风险评估、控制活动、信息与沟 通、内部监督等;重点关注的高风险领域主要包括外部环境风险、投资决策风险、 运营管理风险、资产资金管理风险、法律合规风险、人力资源风险、财务风险及 信息系统风险等。 上述纳入评价范围的单位、业务和事项以及高风险领域具体如下: 海通证券股份有限公司 关于中红普林医疗用品股份有限公司 2023 年度内部控制评价报告的核查意见 海通证券股份有限公司(以下简称"海通证券"或"保荐机构")作为中红 普林医疗用品股份有限公司（以下简称"中红医疗"或"公司"首次公开发行 股票并上市持续督导保荐机构,根据《证券发行上市保荐业务管理办法》《深圳 证券交易所上市公司自律监管指引第 13 号 -- 保荐业务》《深圳证券交易所上 市公司自律监管指引第 2 号创业板上市公司规范运作》《企业 ...

RSM 容诚 非经营性资金占用及其他关联资金 往来情况专项说明 中红普林医疗用品股份有限公司 容诚专字[2024]361Z0173 号 容诚会计师事 骑 缝 容诚会计师事务所(特殊普通合伙) 中国 · 北京 我们接受委托,依据中国注册会计师审计准则审计了中红普林医疗用品股份 有限公司(以下简称中红医疗公司)2023年12月31日的合并及母公司资产负债 表,2023年度的合并及母公司利润表、合并及母公司现金流量表和合并及母公司 所有者权益变动表以及财务报表附注,并于 2024 年 4 月 24 日出具了容诚审字 [2024]361Z0156 号的无保留意见审计报告。 根据中国证券监督管理委员会《上市公司监管指引第 8 号 -- 上市公司资金 往来、对外担保的监管要求》的要求及深圳证券交易所《深圳证券交易所创业板上 市公司自律监管指南第 1 号 -- 业务办理》的规定,中红医疗公司管理层编制了 后附的中红普林医疗用品股份有限公司 2023 年度非经营性资金占用及其他关联资 金往来情况汇总表(以下简称汇总表)。如实编制和对外披露汇总表并保证其真实、 准确、完整是中红医疗公司管理层的责任。 我们对汇总表所载信息与本所 ...

| | 2023 年 | 2022 年 | | 本年比上年 | 2021 年 | | | --- | --- | --- | --- | --- | --- | --- | | | | | | 增减 | | | | | | 调整前 | 调整后 | 调整后 | 调整前 | 调整后 | | 营业收入（元） | 2,105,249,60 | 1,572,568,51 | 1,572,568,513. | 33.87% | 4,909,310,93 | 4,909,310,93 | | | 7.06 | 3.46 | 46 | | 6.58 | 6.58 | | 归属于上市公司股 | - 130,870,579. | 66,916,009.0 | 66,916,009.08 | -295.57% | 2,341,903,87 | 2,341,903,87 | | 东的净利润（元） | 41 | 8 | | | 9.36 | 9.36 | | 归属于上市公司股 东的扣除非经常性 | - 215,645,541. | - 69,820,974.4 | -68,580,271.27 | -214.44% | 2,245,8 ...

RSM 容诚 2023 年度营业收入扣除情况的 专项审核报告 中红普林医疗用品股份有限公司 容诚专字[2024]361Z0174 号 容诚会计师事务所(特殊普通合伙) 容诚会计师 编 中国 · 北京 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http:///am.of.gov.cn）"进行查 " 目 | 序号 | 内 发 | 页码 | | --- | --- | --- | | | 营业收入扣除情况的专项审核报告 | 1-3 | | 2 | 营业收入扣除情况表 | | 关于中红普林医疗用品股份有限公司 2023 年度营业收入扣除情况的专项审核报告 容诚专字[2024]361Z0174 号 中红普林医疗用品股份有限公司全体股东: 我们接受委托,按照中国注册会计师审计准则审计了中红普林医疗用品股份 有限公司(以下简称中红医疗公司)2023年度财务报表,并于 2024年 4 月 24 日 出具了容诚审字[2024]361Z0156 号的无保留意见审计报告。在此基础上我们审核 了后附的中红医疗公司管理层编制的《中红普林医疗用品股份有限公司 2023 年度 营业收入扣除情况表》(以下简称营业收入扣除情况 ...

为规范募集资金的管理和使用,切实保护投资者利益,公司根据《中华人民 共和国公司法》《中华人民共和国证券法》和《深圳证券交易所创业板股票上市 海通证券股份有限公司 关于中红普林医疗用品股份有限公司 2023 年募集资金存放与使用情况的核查意见 海通证券股份有限公司(以下简称"海通证券"或"保荐机构")作为中红 普林医疗用品股份有限公司(以下简称"中红医疗"或"公司"首次公开发行 股票并上市/持续督导保荐机构,根据《证券发行上市保荐业务管理办法》《上市 公司监管指引第 2 号 -- 上市公司募集资金管理和使用的监管要求(2022 年修 订 >》《深圳证券交易所股票上市规则》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 13 号 -- 保荐业务》《深圳证券交易 所上市公司自律监管指引第 2 号-创业板上市公司规范运作》等有关规定，对中 红医疗 2023 年度募集资金的存放和使用情况进行了核查,具体情况如下: 一、募集资金基本情况 (一) 募集资金实际到位及存放情况 经中国证券监督管理委员会《关于同意中红普林医疗用品股份有限公司首次 公开发行股票注册的批复》(证监许可[2021]758 ...

" 假5财 | 容 诚 审计报告 中红普林医疗用品股份有限公司 容诚会计师事务所(特殊普通合伙) 容诚会计 容诚审字[2024]361Z0156 号 中国 · 北京 您可使用手机"扫一短"或进入"注册会计师行业统一监管平台（http://acc.mor.cov.co.） "进行营品 您可使用手机"扫一短"或进入"注册会计师行业统一监管平台（http://acc.mor.com.cn） 我打造网: 翡 目 录 | 序号 | 答 | 项码 | | --- | --- | --- | | 1 | 审计报告 | I-6 | | 2 | 合并资产负债表 | 7 | | 3 | 合并利润表 | 8 | | 4 | 合并现金流量表 | 9 | | 5 | 合并所有者权益变动表 | 10 | | 6 | 母公司资产负债表 | 11 | | 7 | 母公司利润表 | 12 | | 8 | 母公司现金流量表 | 13 | | 9 | 母公司所有者权益变动表 | 14 | | 10 | 财务报表附注 | 15 - 147 | 审计报告 容诚审字[2024]361Z0156 号 中红普林医疗用品股份有限公司全体股东: 一、审计意见 ...

中红普林医疗用品股份有限公司 章程 1 | 第一章总则 3 | | --- | | 第二章经营宗旨和范围 4 | | 第三章股份 5 | | 第一节股份发行 5 | | 第二节股份增减和回购 5 | | 第三节股份转让 7 | | 第四章公司党组织 8 | | 第五章股东和股东大会 9 | | 第一节股东 9 | | 第二节股东大会的一般规定 12 | | 第三节股东大会的召集 18 | | 第四节股东大会的提案与通知 19 | | 第五节股东大会的召开 21 | | 第六节股东大会的表决和决议 24 | | 第六章董事会 29 | | 第一节董事 29 | | 第二节独立董事 32 | | 第三节董事会 35 | | 第四节董事会专门委员会 41 | | 第七章高级管理人员 43 | | 第八章监事会 45 | | 第一节监事 45 | | 第二节监事会 46 | | 第九章财务会计制度、利润分配和审计 48 | | 第一节财务会计制度 48 | | 第二节内部审计 53 | | 第三节会计师事务所的聘任 53 | | 第十章通知和公告 54 | | 第一节通知 54 | | 第二节公告 55 | | 第十 ...

中红普林医疗用品股份有限公司 2023 年年度报告商誉减值 证券代码：300981 证券简称：中红医疗 中红普林医疗用品股份有限公司 2023 年度商誉减值测试报告 一、是否进行减值测试 是 □否 二、是否在减值测试中取得以财务报告为目的的评估报告 是 □否 | 资产组名称 | 评估机构 | 评估师 | 评估报告编号 | 评估价值类型 | 评估结果 | | --- | --- | --- | --- | --- | --- | | 包含商誉的 | | | | | 采用收益法评估，截止评估基准 | | 桂林恒保健 | 同致信德（北 | | 同致信德评报 | | 日，中红医疗拟进行商誉减值测试 | | 康防护有限 | 京）资产评估 | 于泓淼、刘佳 | 字（2024）第 | 可收回金额 | 涉及的包含商誉的恒保健康相关资 | | 公司相关资 | 有限公司 | | 010087 号 | | 产组账面值为 86,080 万元，评估 | | 产组 | | | | | 值为 75,810 万元。 | | 包含商誉的 | | | | | 采用预计未来现金流量的现值评 | | 深圳迈德瑞 | 同致信德（北 | | 同致信德评 ...